Neurocrine Biosciences Reports Second Quarter 2008 Results Earthtimes (press release), UK - ... successfully completed a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression. ... |
Wednesday, July 30, 2008
Neurocrine Biosciences Reports Second Quarter 2008 Results - Earthtimes (press release)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment